Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.5% - Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price dropped 1.5% during trading on Tuesday . The stock traded as low as $6.65 and last traded at $6.66. Approximately 494,945 shares were traded during trading, a decline of 91% from the average daily volume of 5,738,237 shares. The stock had previously closed at $6.76.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Needham & Company LLC cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a report on Wednesday, September 4th. Jefferies Financial Group reduced their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research report on Tuesday, September 3rd. Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Tuesday, September 3rd. Finally, KeyCorp cut their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, July 11th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $9.40.

Recursion Pharmaceuticals Trading Down 2.2 %

The company has a market capitalization of $1.57 billion, a P/E ratio of -4.15 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The business's 50-day moving average price is $6.73 and its two-hundred day moving average price is $7.76.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. The firm's revenue was up 30.9% on a year-over-year basis. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $8.13, for a total transaction of $48,780.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares in the company, valued at approximately $4,353,265.41. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, COO Tina Marriott sold 6,000 shares of the firm's stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the completion of the transaction, the chief operating officer now directly owns 535,457 shares of the company's stock, valued at $4,353,265.41. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the business's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at approximately $4,606,442.24. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 201,682 shares of company stock worth $1,332,933. Company insiders own 15.75% of the company's stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in Recursion Pharmaceuticals by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company's stock worth $154,459,000 after acquiring an additional 158,376 shares in the last quarter. Wedmont Private Capital boosted its holdings in shares of Recursion Pharmaceuticals by 11.8% in the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company's stock valued at $172,000 after buying an additional 2,000 shares during the last quarter. TB Alternative Assets Ltd. bought a new position in shares of Recursion Pharmaceuticals in the first quarter valued at $706,000. Oxinas Partners Wealth Management LLC acquired a new position in Recursion Pharmaceuticals during the first quarter worth $122,000. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in Recursion Pharmaceuticals by 12.6% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company's stock worth $103,317,000 after acquiring an additional 1,159,023 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.